Difference between revisions of "NEUROPATHY-CIDP"
(Imported from text file) |
(Imported from text file) |
||
| Line 3: | Line 3: | ||
<br/> | <br/> | ||
<br/>2. It begins insidiously, progresses slowly and attains maximum severity after several months. | <br/>2. It begins insidiously, progresses slowly and attains maximum severity after several months. | ||
<br/> | |||
<br/>3. Chronic symmetric sensorimotor loss, EMG findings of demyelination, and elevated CSF protein, generalised areflexia, duration > 8 wks define the illness. | <br/>3. Chronic symmetric sensorimotor loss, EMG findings of demyelination, and elevated CSF protein, generalised areflexia, duration > 8 wks define the illness. | ||
<br/> | <br/> | ||
Latest revision as of 11:07, 20 March 2023
SUMMARY
1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired immune neuropathy, relapsing or progressive over > 8 weeks.
2. It begins insidiously, progresses slowly and attains maximum severity after several months.
3. Chronic symmetric sensorimotor loss, EMG findings of demyelination, and elevated CSF protein, generalised areflexia, duration > 8 wks define the illness.
4. Unlike in Guillain-Barre, glucocorticoids hasten recovery and prevent relapse in CIDP. Plasmapheresis or IVIG are also standard treatments.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
